Document is current
Any future updates will be listed below
-
Authors
Muñoz‐Espín, Daniel https://orcid.org/0000-0002-0550-9514
Rovira, Miguel https://orcid.org/0000-0002-1391-8465
Galiana, Irene
Giménez, Cristina
Lozano‐Torres, Beatriz
Paez‐Ribes, Marta
Llanos, Susana
Chaib, Selim
Muñoz‐Martín, Maribel
Ucero, Alvaro C
Garaulet, Guillermo
Mulero, Francisca
Dann, Stephen G
VanArsdale, Todd
Shields, David J
Bernardos, Andrea
Murguía, José Ramón
Martínez‐Máñez, Ramón
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
-
Funding
Funding for this research was provided by:
Secretaría de Estado de Investigación, Desarrollo e Innovación (MAT2015‐64139‐C4‐1‐R)
H2020 European Research Council
Instituto de Salud Carlos III (DTS16/00205)
European Regional Development Fund
European Social Fund
Institut Ruđer Bošković
Fundación Botín
Banco Santander
“la Caixa” Foundation
Cancer Research UK (C9685‐A25177)
Cancer Research UK (RG86786)
Generalitat Valenciana (PROMETEOII/2014/047)
Pfizer
- License Information
-
More Information
Article History
Received: 23 May 2018
Revised: 20 June 2018
Accepted: 22 June 2018
First Online: 16 July 2018
Conflict of interest
: S.D., T.V., and D.J.S. are employees of Pfizer Inc. and hold shares in the company. J.R.M., R.M.‐M., and M.S. are founders of Senolytic Therapeutics, S.L. (Spain) and Senolytic Therapeutics, Inc. (USA) aimed at developing senolytic therapies.
